Volume 25, Issue 3 (Avicenna Journal of Clinical Medicine-Autumn 2018)                   Avicenna J Clin Med 2018, 25(3): 134-141 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mahabadi-Ashtiyani E, Sheikh V, Borzouei S, Salehi I, Alahgholi-Hajibehzad M. Effect of Sitagliptin and Vitamin D3 on Secretion of IL-6 and TNF-α Inflammatory Factors in Patients with Type 2 Diabetes. Avicenna J Clin Med 2018; 25 (3) :134-141
URL: http://sjh.umsha.ac.ir/article-1-1771-en.html
1- Assistant Professor, Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran , mhajibehzad@yahoo.com
Abstract:   (4207 Views)
Background and Objective: Diabetes mellitus is one of the most commonly reported diseases that is associated with insulin resistance and increased blood glucose levels.  The aim of this study was to determine the probable anti-inflammatory effects of sitagliptin and vitamin D3 (VitD3) on pro-inflammatory IL-6 and TNF-α in patients with type 2 diabetes mellitus (T2DM).
Materials and Methods: In this case-control study, 20 blood samples of patients with T2DM and healthy controls (HCs) were collected (n=20). Peripheral blood mononuclear cells (PBMCs) were isolated using the Ficoll-Paque method and cultured with Phytohemagglutinin (PHA) in the presence or absence of sitagliptin and VitD3 for 4 days. The enzyme-linked immunosorbent assay was used to analyze the levels of IL-6 and TNF-α produced by PBMCs.
Results: After PHA stimulation, the production of IL-6 was increased significantly in T2DM patients compared to HCs (P=0.03) . Compared to PHA cultures, sitagliptin and VitD3 resulted in the reduction of IL-6 production in patients (P≤0.001, P≤0.001), and HCs (P=0.03, P=0.02), respectively. Moreover, with regard to the cultures with sitagliptin or VitD3, sitagliptin with VitD3 reduced the level of IL-6  in both groups of patients (P=0.02, P=0.002) and HCs (P=0.002, P=0.03). There was a significant reduction in the level of TNF-α by sitagliptin with VitD3 in patients (P=0.04, P=0.002) and HCs (P=0.04, P=0.03) , compared to cultures with sitagliptin or VitD3.
Conclusion: According to the results, it can be concluded that the combined use of sitagliptin and VitD3 is more influential regarding the anti-inflammatory effects on patients. In addition, the reduction of sitagliptin dose may result in decreasing its possible side effects
Full-Text [PDF 345 kb]   (1184 Downloads)    
Type of Study: Original | Subject: Other Clinical Specialties

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb